flipper44,
Great points! Since not long before 2014 when big pharma’s own research showed that dendritic cell therapy was the lynchpin for improved outcomes with their own immunotherapies, and Direct was proving itself, NWBO has been in the crosshairs of those being threatened most. Since then many have been seeking any potential work arounds that could keep them from having to admit they were not working with the high road correct approach of safety first from using autologous cells and personalized treatment. Just imagine if all the money spent on these futile trials would have been used instead to develop mutually beneficial combos. Many billions of research dollars could have moved cancer treatment progress forward much faster but at the cost perhaps of many more billions in profit because of not doing so.
Ask the actuaries and my guess is the profit trail was followed over moving patient treatment forward into the 21st century. Best wishes.
News 
Market Data 
Discover 
